Cancer Facts & Figures 2025
The 2025 annual report provides estimated numbers of new cancer cases, deaths, survivors and statistics on prevention, early detection, and treatment.
Related Articles
PathElective
PathElective is an interactive pathology website for medical students and residents seeking a virtual pathology elective experience or introductory pathology information for junior pathology residents.…
Home – The American Society for Clinical Investigation
This is the home page for The American Society for Clinical Investigation website.
Host Transition: Meet Cancer Stories New Host Dr. Mikkael Sekeres | ASCO Publications
We say thank you to current Cancer Stories host, Dr. Lidia Schapira, and welcome Cancer Stories new host, Dr. Mikkael Sekeres.
Evaluating the Adequacy of Central Line-Associated… : Critical Care Explorations
med to assess the prevalence and outcomes of central CLABSI at our institution, to identify opportunities for improvement, appropriately direct efforts for infection reduction, and…
Ponsegromab Reduces Symptoms Linked to Cancer Cachexia, Elevated GDF-15
Patients in the ponsegromab group had significantly greater weight gain and physical activity than those in the placebo arm in a phase 2 trial.
Welcome! You are invited to join a webinar: 2024 AHA Perioperative Guidelines for NCS. After registering, you will receive a confirmation email about joining the webinar.
Objectives: 1. Review the updated guideline for perioperative cardiovascular management of surgical patients 2. Summarize the most important changes 3. Understand the importance of national…
Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma
Key PointsWith a median follow-up of 24.2 months, the 2-year progression-free survival of patients treated with AN+AD was 88%.AN+AD led to an 88% CR rate…
Cancer statistics, 2025
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data…
Combined targeted modality in cHL: a risky bet?
In this issue of Blood, Lee et al1 conclude that the brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (BV-N-AD) regimen shows a tolerable safet
Genetic alteration of class I HLA in cutaneous T-cell lymphoma
Key PointsGenetic alteration of class I HLA genes is common in advanced cutaneous T-cell lymphoma but rarely affects total class I HLA expression.Genetic e